Physician profile
Stephanie Boyd Mcbee
NPI 1346795804
$1,154.28
in general payments reported to CMS, 2019-2025
16 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.17 · 2022: $145 · 2023: $165 · 2024: $369 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $263.97 | 2023-2025 | |
| Amgen INC. | $218.86 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $160.62 | 2022-2024 | Farxiga |
| Abbott Laboratories | $108.37 | 2024 | Cardiomems |
| Baxter Healthcare | $75.04 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $64.57 | 2022-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.15 | 2021-2024 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $37.85 | 2024 | |
| Scpharmaceuticals INC. | $36.80 | 2024-2025 | |
| Esperion Therapeutics, INC. | $33.01 | 2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $24.44 | 2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $21.16 | 2025 | Camzyos |
| Merck Sharp & Dohme LLC | $19.17 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.20 | 2024 | Jardiance |
| Tactile Systems Technology INC | $15.77 | 2024 | Flexitouch Plus, Entre Plus |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cashflow Solutions, LLC | $14.30 | 2023 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Mcbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.